Bridging nanotechnology research and clinical application in oncology.
Miragen develops a patented portfolio spanning early-detection biosensors and brain-targeted nanotherapeutics — built to lower the cost of diagnosis, reduce systemic toxicity, and bring laboratory science to the clinic.
Five platforms, one ecosystem
A diagnostic biosensor paired with four delivery technologies — designed so early detection and targeted therapy work as one continuous system, not separate products.
- › Label-free detection of breast & brain cancer biomarkers
- › Non-invasive nose-to-brain delivery, bypassing the BBB
- › Post-surgical implants engineered against relapse
Three unmet needs, one integrated approach.
Cancer outcomes in India are shaped less by biology than by access — to early diagnosis, to therapies that reach the brain, and to care that patients can afford. Miragen's platforms are built directly against those three constraints.
Non-invasive brain delivery
Intranasal nanotubes bypass the blood-brain barrier without surgery or systemic infusion.
Lower systemic toxicity
Localized and targeted release reduces the whole-body drug burden of conventional regimens.
Affordable early diagnostics
A portable biosensor targets sub-₹1,000 per test, against ₹8,000–30,000 for imaging.
Bench-to-bedside focus
Every platform is built with a defined clinical translation and regulatory pathway in mind.
Five platforms, built to work together
A diagnostic device and four therapeutic delivery systems, unified by a single goal: catch cancer earlier, and treat it more precisely.
SPR Biosensor
Label-free, portable optical biosensor for early detection of breast and brain cancer biomarkers from a liquid biopsy.
View platform →BBB-Penetrating Nanotubes
Self-assembled, transferrin-targeted nanotubes that deliver therapy nose-to-brain, bypassing the blood-brain barrier.
View platform →Injectable Self-Gelling Wafer
An in-situ gelling implant placed after surgery, conforming to irregular cavities to prevent local tumor recurrence.
View platform →Transdermal Nanoparticles
A lipid-based delivery system that penetrates beyond the stratum corneum for therapeutics and micronutrients.
View platform →Microneedle Patches
A pain-free, self-applicable patch for delivering vitamins, micronutrients, and small molecules through the skin.
View platform →Building the next platform
Advanced formulations in nanotherapeutics and diagnostics are in active development behind our two granted patents.
See the IP roadmap →The clinical gap Miragen is built to close
Brain and breast cancer outcomes in India lag global benchmarks largely because of late detection and limited access to targeted therapy.
Survival under 7% at Grade IV
Glioblastoma causes disproportionate mortality relative to its incidence, driven by late-stage diagnosis, blood-brain barrier impermeability, and a 90% local recurrence rate after surgery.
40–55% survival in India vs. ~91% globally
The gap is driven almost entirely by detection stage — most cases globally are caught at Stage I/II, while in India most present at Stage III/IV, multiplying treatment cost and reducing survival.
Sources: GLOBOCAN 2024; Miragen internal market analysis. Cost ranges reflect current standard-of-care pricing in India.
Built for partners — and for the patients behind the data
Co-development, licensing, and clinical validation
Engage with a validated, patent-protected platform across diagnostics and delivery — from R&D advisory through full technology transfer.
- Co-development and technology licensing
- GMP scale-up and manufacturing transfer
- Clinical validation through hospital networks
What this means for the future of cancer care
Earlier detection and gentler treatment shouldn't be a privilege. Our platforms are designed to make both more accessible, starting in India.
- Lower-cost screening for high-risk populations
- Treatments that avoid invasive surgery where possible
- Research grounded in peer-reviewed, published science
Led by the science, not just the strategy
Miragen is directed by Dr. Puja Sandbhor, a neuro-oncology nanomedicine researcher whose work spans IIT Bombay and Johns Hopkins University School of Medicine, with two granted Indian patents and 10+ peer-reviewed publications underpinning the company's platforms.
Read the full profile →Specialized in blood-brain barrier biology, nanomedicine formulation, and translational cancer therapeutics.